Evidence map›Paper›PMID 29899571›Full record

Trial reportBone marrow transplantation2019

The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.

Jessica Hochberg, Stacey Zahler, Mark B Geyer, Nan Chen, Jennifer Krajewski, Lauren Harrison, Olga Militano, M Fevzi Ozkaynak, Alexandra C Cheerva, Julie Talano and 6 more

Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. [Efficacy and prognostic factors in children with non-core binding factor acute myeloid leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Jessica HochbergDepartments of Pediatrics, Valhalla, NY, USA.
Stacey ZahlerPediatric Institute, Cleveland Clinic Children's, Cleveland, Ohio, USA.
Mark B GeyerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5248-9117
Nan ChenDepartments of Pediatrics, Valhalla, NY, USA.
Jennifer KrajewskiDepartment of Pediatrics, Hackensack University Medical Center, Hackensack, NJ, USA.
Lauren HarrisonDepartments of Pediatrics, Valhalla, NY, USA.
Olga MilitanoDepartments of Pediatrics, Valhalla, NY, USA.
M Fevzi OzkaynakDepartments of Pediatrics, Valhalla, NY, USA.
Alexandra C CheervaDepartment of Pediatrics, University of Louisville, Louisville, KY, USA.ORCID 0000-0002-6494-1817
Julie TalanoDepartment of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
Theodore B MooreDepartment of Pediatrics, University of California at Los Angeles, Los Angeles, CA, USA.
Alfred P GillioDepartment of Pediatrics, Hackensack University Medical Center, Hackensack, NJ, USA.
Mark C WaltersDepartment of Hematology/Oncology, Children's Hospital and Research Center of Oakland, Oakland, CA, USA.
Lee Ann Baxter-LoweDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Carl HambyDepartments of Microbiology and Immunology, Valhalla, NY, USA.
Mitchell S CairoDepartments of Pediatrics, Valhalla, NY, USA. Mitchell_Cairo@nymc.edu.
New York Medical College · USHackensack University Medical Center · USChildren's Hospital of Los Angeles · USCleveland Clinic · USMedical College of Wisconsin · USMemorial Sloan Kettering Cancer Center · USOakland University · USUniversity of California, Los Angeles · USUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute leukemias in children with CR3, refractory relapse, or induction failure (IF) have a poor prognosis. Clofarabine has single agent activity in relapsed leukemia and synergy with cytarabine. We sought to determine the safety and overall survival in a Phase I/II trial of conditioning with clofarabine (doses 40 - 52 mg/m

Indexed as

Acute DiseaseAdolescentAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolClofarabineCytarabineFemaleHematopoietic Stem Cell TransplantationHumansInfantLeukemiaLeukemia, Myeloid, AcuteMaleMyeloablative AgonistsPrecursor Cell Lymphoblastic Leukemia-LymphomaClofarabineCytarabineMyeloablative Agonists

Identifiers

PMID29899571
OpenAlexW2808276676

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.